

Opinion

Noblesse oblige of the WMA in peril: Save its honor at the Diamond Anniversary¹

Takeo Saio²

Department of Internal Medicine and Psychiatry, Fuji Toranomom Orthopedic Hospital

Abstract

At the 60th anniversary of the Declaration of Helsinki (DoH), its core principle to prioritize patient interests to scientific goal has been exposed to peril.

Though a critic sparsely points out that this principle contradicts the placebo clause, the author conceives that the placebo clause should be changed because it contradicts the CIOMS guidelines for implementing the DoH in resource-limited settings.

This discrepancy of opinion is attributable from the difference between utilitarianism and deontology. We should engrave that the most part of the World Medical Association (WMA)'s statements have been based on deontology until now.

The critic mentioned above also argues that research regulations issued by regulatory authorities are enough for protecting research participants. However, the WMA is not a regulatory authority but a professional body controlled by the professional autonomy of the medical doctors around the world. Thus, the WMA can voluntarily constitute its basic principles including the core principle of the DoH should not be constrained by regulatory authorities.

The WMA should save its honor through procedural justice with ensuring accountability toward this contradiction between placebo clause and core principles of the DoH.

Key words

Declaration of Helsinki, utilitarianism, deontology, placebo-controlled trial, procedural justice

¹ This article was expanded from the manuscript which was submitted to *JAMA* as letter to editor, responding the article by Menikoff (reference 1) but rejected. Preprint version in English was published in the website of this journal on October 10, 2024, just before the adoption of the 2024 revision of the Declaration of Helsinki, October 19, 2024. The printed issue of this journal published in February 25, 2025 includes only Japanese translation from the final English version, which replaced the preprint in the journal website.

² K&S Consulting Office for Occupational Mental Health

1. The Core Principle in peril

1.1 Annoying suggestion to terminate the core principle

A thought-provoking article was published in the *Journal of the American Medical Association (JAMA)*¹ just before the last one of the series of regional meetings for the revision of the Declaration of Helsinki (DoH)² held by the World Medical Association (WMA) and the American Medical Association (AMA), at Washington DC in August 2024. It was written by Jerry Menikoff, the immediate past Director of the United States (US) Office for Human Research Protection (OHRP).

He suggested to terminate the core principle of the DoH to prioritize patients' interests to the goal of research. This crucial principle has been kept long time in its paragraph 8, or in paragraph 7 in the draft revision for the second public consultation. He recommends to replace this core principle of the DoH with the statement of the exact opposite one in celebrating its 60th-year anniversary to adopt the revised version in October 2024.

1.2 Physician's obligation versus scientific goal

His recommendation discredits all the other deontological statements issued by the WMA, including, but not limited to, the Declaration of Geneva³, which was derived from Hippocratic Oath, the International Code of Medical Ethics⁴ (both of them are quoted in the DoH) as well as the Declaration of Lisbon on the Rights of the Patient⁵.

We, physicians, with conscientious sense of duty of care, would surely refuse to conduct research if we were mandated by any government officials to sacrifice this core principle to prioritize scientific goal.

Such conflict may happen in such a case as the consultation process of clinical trial design among regulatory authorities or sponsor companies and physician-investigators.

1.3 Clear distinction between research and practice

Menikoff argues based on logical distinction between research and clinical practice as described in the Belmont Report⁶. He makes out that the principle leads "therapeutic misconception" which means patients misunderstand as they will receive the best care in research.

His standpoint is the same as some US bioethicists in placebo debates arguing that setting condition of comparative study to be "clinical equipoise" is actually deceptive⁷ because the study's true aim is to prove the significant difference of efficacy between comparative arms.

1.4 Utilitarianism versus deontology

The Belmont Report also suggests to ensure maximizing benefit of individual and the society to outweigh the minimized risk of research. The problem would be difference of the level of acceptable

risk between utilitarian justification and deontological obligation⁸.

The utilitarian stresses the distinction between research and practice, although both may “*occur together (as in research designed to evaluate a therapy)*”⁶. Thus, they argue that participation in research must be based on willingness to accept the risks specific to research.

The deontologist requires additionally that the risks specific to research should be limited to the extent that they do not undermine the physician's responsibility to provide the best care to the patients, paying special attention to the Belmont Principle to state that “*the risks and benefits affecting the immediate research subject will normally carry special weight*”⁶.

2. Placebo debate

2.1 Acceptable risk in placebo-controlled trials

Menikoff points out the critical discordance in the DoH to be the one between this core principle and placebo clause (paragraph 33). This analysis is apparently correct, but the author refutes him with pointing out that what should be amended is not the core principle but rather the inappropriate placebo clause.

The DoH tolerates placebo study when there is proven intervention if there is “no increase of *risk of serious or irreversible harm*”. We asserted that this inconsistency must be corrected by means of revision of this threshold to “*minor increase above minimal risk*” in accord with the Guidelines by the Council for International Organizations of Medical Sciences (CIOMS)^{8, 9}. CIOMS guidelines were developed for implementing the DoH in resource-limited settings.

However, there is no change in the WMA’s proposed revision of the DoH. This generous stance of the DoH to allow high-risk placebo study (to cause e.g., burden, pain of long lasting but not “serious” and not “irreversible”) led vehement objection of the DoH from Latin American communities⁸.

2.2 Fairness and accountability in procedural justice

During the process for 2024 revision of the DoH, a regional meeting to discuss this topic involving Latin American community was organized by the WMA, in February of 2023. Although dissenting opinions to the placebo clause were expressed, they were insincerely dismissed without disclosing any reasons as well as rational arguments why such opinions were turned down.

For such a topic that has been raising international controversy over the decades, fairness and accountability in due process is extremely important in terms of procedural justice.

2.3 Methodology to preserve duty of care

In order to observe the core principles, physician-investigators are required to set criteria for early termination of study participation of each patient to give rescue treatments by means of “early

escape” on the grounds of careful observation about each patient as well as setting criteria for study termination with reviewing the interim analysis of the Independent Data Monitoring Committees¹⁰.

The core principles of the DoH has encouraged research community to explore methodological development to prove the effectiveness of treatments for serious diseases through the Bayesian statistical analysis and/or the use of real-world data¹¹¹²¹³.

3. Professional autonomy in peril

3.1 Do regulations take precedence over professional autonomy?

Menikoff also claims that the core principle that physicians must prioritize patients’ interest to the goal of research could be removed on the ground that research risks would be controlled by research regulations. Yet, the US legislation on human research including research regulations are applicable only to research of medicinal products and others with governmental funding.

His contestation is similar with the administrative decision of the US Food and Drug Administration (FDA) which was criticized when they replaced the DoH with ICH-GCP in its regulation on research outside the US with the results submitted to the US for new drug approval¹⁴.

3.2 Laws for physicians losing autonomy

The WMA is not a regulatory authority but a professional body controlled by the professional autonomy of the medical doctors around the world. Thus, the WMA can voluntarily constitute its basic principles including the core principle of the DoH should not be constrained by regulatory authorities.

In fact, clinicians who already lost neither professional autonomy¹⁵ nor effective professionally-led regulations¹⁶ might be acquisitive of maximizing their economic self-interest in exchange for patients’ health. Such iniquities of physicians might be discouraged by the righteous legislations including criminal punishments mainly made by non-physicians.

This would be similar to the code of conduct, derived from Nuremberg Code¹⁷, which was first proposed just before the adoption of the first version of the DoH. It was proposed as the result of collaboration with lawyers but rejected by professional society of physicians¹⁸.

4. Diamond anniversary with contradiction

In the countries and/or research areas with effective research regulations, abolishment of its core principles would lead to silent neglect of the DoH. It may be easier to get into the line with written regulations than following one's own clear conscience comparing with the internal and autonomous code of conduct in oneself. Furthermore, the DoH without core principles shall obviously loses the

power in the jurisdictions which lack sufficient regulations, and eventually its authority will disappear from the scope of physicians.

At the 60 years of the diamond anniversary, noblesse oblige of the WMA is now in its jeopardy. The core principle criticized by Menikoff seems to be defended. However, controversial placebo clause does not seem to be changed, keeping contradiction with the core principle.

Conflict of interest

There is no conflict of interest to be disclosed related to this article.

Acknowledgment

The author appreciates Chieko Kurihara for her advice with the expertise of research ethics.

References

- ¹ Menikoff J. Protecting Participants Is Not the Top Priority in Clinical Research. *JAMA*. 2024 Jun 20. doi: 10.1001/jama.2024.7677. Epub ahead of print. PMID: 38900422.
- ² World Medical Association. WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and last amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013. <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
- ³ World Medical Association. WMA Declaration of Geneva. Adopted in September 1948, last amended in October 2017. Available at: <https://www.wma.net/policies-post/wma-declaration-of-geneva/>
- ⁴ World Medical Association. WMA International Code of Medical Ethics. Adopted in October 1949, last amended in October 2022. Available at: <https://www.wma.net/policies-post/wma-international-code-of-medical-ethics/>
- ⁵ The World Medical Association. WMA Declaration of Lisbon on the Rights of the Patient. Adopted in September/October 1981, last reaffirmed in April 2015. <https://www.wma.net/policies-post/wma-declaration-of-lisbon-on-the-rights-of-the-patient/>
- ⁶ The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. 18 Apr 1979. <https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/read-the-belmont-report/index.html>
- ⁷ Miller FG, Brody H. Clinical equipoise and the incoherence of research ethics. *J Med Philos*. 2007 Mar-Apr;32(2):151-65. doi: 10.1080/03605310701255750. PMID: 17454420.
- ⁸ Kurihara C, Greco D, Dhali A, Saio T, Tsubaki H. Ethics of placebo-controlled trials: historical analysis including experiences during the COVID-19 pandemic. In: Kurihara C, Greco D, Dhali A, editors. *Ethical innovation for global health: pandemic, democracy and ethics in research*. Springer; 2023. p. 195-224.
- ⁹ Council for International Organizations of Medical Sciences. International ethical guidelines for health-related research involving humans. 2016. <https://cioms.ch/publications/product/international-ethical-guidelines-for-health-related-research-involving-humans/>
- ¹⁰ International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: choice of control group and related issues in clinical trials E10. 2000. https://database.ich.org/sites/default/files/E10_Guideline.pdf. https://database.ich.org/sites/default/files/E10_Guideline.pdf
- ¹¹ [Draft] U.S. Food and Drug Administration. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. February 2023. Available online at: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products> (accessed December 22, 2023)
- ¹² Council for International Organizations of Medical Sciences. Real-world data and real-world evidence in regulatory decision making: Report of the CIOMS Working Group XIII. May 2024. <https://cioms.ch/publications/product/real-world-data-and-real-world-evidence-in-regulatory-decision-making/>

¹³ Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research; Oncology Center of Excellence, U.S. Department of Health and Human Services Food and Drug Administration. Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. July 2024. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory>

¹⁴ Lurie P, Greco DB. US exceptionalism comes to research ethics. *Lancet*. 2005 Mar 26-Apr 1:365(9465):1117-9.

¹⁵ World Medical Association. WMA Declaration of Seoul on Professional Autonomy and Clinical Independence. Adopted by the 59th WMA General Assembly, Seoul, Korea, October 2008, amended by the 69th WMA General Assembly, Reykjavik, Iceland, October 2018. <https://www.wma.net/policies-post/wma-declaration-of-seoul-on-professional-autonomy-and-clinical-independence/>

¹⁶ WMA Declaration of Madrid on Professionally-led Regulation. Adopted by the 60th WMA General Assembly, New Delhi, India, October 2009 and revised by the 70th WMA General Assembly, Tbilisi, Georgia, October 2019. <https://www.wma.net/policies-post/wma-declaration-of-madrid-on-professionally-led-regulation/>

¹⁷ The International Military Tribunal. Trials of war criminals before the Nuremberg Military Tribunals under Control Council law no. 10 Nuremberg, October 1946–April 1949, vol. 2. p. 181–2. (The Nuremberg Code.)

¹⁸ Schmidt U. From Nuremberg to Helsinki: Historicizing the codification of post-war research ethics. In: Kurihara C, Greco D, Dhali A, editors. *Ethical innovation for global health: pandemic, democracy and ethics in research*. Springer; 2023. p.149-174.

(English version submitted: October 6, 2024)

(Preprint published: October 10, 2024)

(English and Japanese versions accepted: January 15, 2025)